Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis
NCT ID: NCT02193139
Last Updated: 2015-08-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
195 participants
INTERVENTIONAL
2013-12-31
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis
NCT02563899
Use of Oxybutynin for Treating Hyperhidrosis: A Placebo-control Study
NCT01310712
Study of Glycopyrronium in Axillary Hyperhydrosis
NCT02530281
Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis
NCT02553798
Use of Oxybutynin to Treat Axillary Hyperhidrosis
NCT01118429
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
WL8713, 6 mg
6 mg WL8713 administered daily
WL8713, 6 mg
WL8713, 12 mg
12 mg WL8713 administered daily
WL8713, 12 mg
WL8713, 18 mg
18 mg WL8713 administered daily
WL8713, 18 mg
WL8713, 24 mg
24 mg WL8713 administered daily
WL8713, 24 mg
Placebo
placebo administered daily
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
WL8713, 6 mg
WL8713, 12 mg
WL8713, 18 mg
WL8713, 24 mg
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Poor quality of life rating on the Hyperhidrosis Disease Severity Scale (score of 3 or 4)
* Has a baseline gravimetric measurement of spontaneous resting sweat production of ≥100 mg/10 min at room at room temperature in at least one axilla
* Meets at least two of the following criteria (self-reported):
* sweating is bilateral and symmetrical
* excessive sweating impairs daily activities
* subject experiences at least one sweating episode per week
* excessive sweating onset was earlier than age 25 years
* has a positive family history for excessive sweating
* cessation of sweating during sleep
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Watson Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Watson Clinical Site
San Diego, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OH1304
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.